Back to top
more

Myriad Genetics, Inc. (MYGN)

(Delayed Data from NSDQ)

$30.21 USD

30.21
940,294

+0.11 (0.37%)

Updated Feb 25, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 21% (199 out of 253)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Myriad Genetics (MYGN) Beats on Q2 Revenues, Earnings in Line

Myriad Genetics' (MYGN) sales in majority of the operating segments improved in the quarter despite pandemic-led business challenges.

Myriad Genetics (MYGN) Reports Q2 Loss, Tops Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 0.00% and 4.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics' (MYGN) Prolaris Test Study Outcome Favorable

Myriad Genetics' (MYGN) new study combines a Prolaris molecular risk score approach with a clinical model for predicting a patient's benefit from androgen deprivation therapy.

New Study Favors Myriad Genetics' (MYGN) GeneSight Test

Myriad Genetics' (MYGN) GeneSight Psychotropic test is better for predicting patient outcomes and medication blood levels than single-gene testing, per new study.

Earnings Preview: Myriad Genetics (MYGN) Q2 Earnings Expected to Decline

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Myriad Genetics (MYGN), Illumina Partner to Enhance Oncology Arm

Myriad Genetics (MYGN) partners with Illumina to expand the access as well as extend the reach of myChoice CDx through its services offering in the international market.

Why Is Myriad (MYGN) Up 8.3% Since Last Earnings Report?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Myriad Genetics' (MYGN) Q1 Earnings & Revenues Top Estimates

Myriad Genetics' (MYGN) sales in majority of the operating segments plummeted in the quarter owing to the pandemic-led business challenges.

Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 54.55% and 7.86%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Debanjana Dey headshot

Buy 4 Beaten-Down MedTech Value Stocks Amid September Selloffs

Here are some dirt-cheap MedTech value stocks which have been battered by the pandemic-led market meltdown and can be considered for long-term gains.

Myriad (MYGN) Down 0.7% Since Last Earnings Report: Can It Rebound?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Zacks Analyst Blog Highlights: Medtronic, Abbott Laboratories, Myriad Genetics, Zimmer Biomet and General Electric

The Zacks Analyst Blog Highlights: Medtronic, Abbott Laboratories, Myriad Genetics, Zimmer Biomet and General Electric

Urmimala Biswas headshot

3 Coronavirus-Led Threats to MedTech That May Linger

Let us delve deeper to get an insight into the not-so-talked-about but intense threats to MedTech.

ASCO Recommends Myriad Genetics' Test to Treat Ovarian Cancer

Myriad Genetics' (MYGN) myChoice CDx test gets included in ASCO's latest recommendations for advanced ovarian cancer patients.

Myriad Genetics' (MYGN) Q4 Loss Narrower Than Estimated

Myriad Genetics (MYGN) sales in each of the operating segments plummet in the quarter owing to the full-quarter adverse impact of the pandemic.

Myriad Genetics (MYGN) Reports Q4 Loss, Lags Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 13.89% and -2.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Debanjana Dey headshot

3 Affordable MedTech Growth Stocks to Buy Amid Market Unrest

Here are some MedTech stocks which might be a solid investment option amid the coronavirus-battered market conditions.

Myriad Genetics, OptraHEALTH Partner to Offer Cancer Knowledge

Myriad Genetics (MYGN) collaborates with OptraHEALTH to provide an AI-powered cognitive ChatBOT to serve as a genetic health knowledge platform to prospective hereditary cancer patients.

Myriad Genetics Rides on EndoPredict Amid Coronavirus Crisis

Myriad Genetics (MYGN) expects to register an uptick in hereditary cancer volumes on account of its contract with UnitedHealthcare.

Myriad Genetics Unveils New Home DNA Sample Collection Kit

Myriad Genetics' (MYGN) home DNA sample collection test kit for its GeneSight Psychotropic test enables physicians to remotely provide treatment options to patients with mental health issues.

Myriad Genetics' myPath Melanoma Proved Superior Per New Study

Myriad Genetics' (MYGN) myPath Melanoma's accuracy to classify skin lesions, termed as indeterminate by standard pathological review, validated by the latest study.

Zacks.com featured highlights include: Myriad Genetics, Casella Waste, CNH and Schlumberger

Zacks.com featured highlights include: Myriad Genetics, Casella Waste, CNH and Schlumberger

4 Toxic Stocks to Disown or Play Short to Book Profits

If you are a smart investor and can precisely spot toxic stocks, you may gain by resorting to an investing strategy called short selling.